PRODUCT NAME
Product and Service
Comprehensive Drug Enterprises Limited
Benjamin Lee
ADDRESS
Units 811-813, IC Development Centre No. 6 Science Park West Avenue, Hong Kong Science Park, Sha Tin,
CONTACT
+852 26074100
info@cdepharma.com
INTRODUCTION
Comprehensive Drug Enterprises Ltd is a specialty pharmaceutical company that focuses on the development of transmucosal drug delivery, with special emphasis on sublingual and nasal administration of pharmaceuticals. CDE had patented a number of technologies through their research for their product development. CDE was founded in 2005 and located at a research facility in Hong Kong Science Park and their new medical devices production facility in Chongqing was just established in July, 2014. CDE facilitated and grow rapidly in China, Hong Kong and Taiwan and their product market is estimated at about USD 760 million. CDE was teamed by a group of dedicated scientists and professionals with various disciplines associated with financing, sales and marketing, pharmaceutical research and development, and corporate management. CDE leveraged by the local government support and an extensive research collaboration network with universities in Hong Kong, China and the US. CDE worked closely with their business partners in research and development. For example, the leader in nanotechnologies and advanced material, Nano and Advanced Materials Institute Limited (NAMI) is one of CDE major collaborators.
PRODUCT OVERVIEW
The only sublingual Propranolol product in the market, Promptol™, which is for hypertension management and that had already secured a US patent on “Method of Enhancing Absorptions of Transmucosal Administration Formulations”. The invention of Promptol™ brought CDE a Technological Achievement Award from HK Awards for Industries in 2007. In 2012, CDE launched a motion sickness oral solution, Averti™ and it had registered successfully in Hong Kong in the same year. A new product of CDE in Anti-itching, Antipruritic Hydrogel had been approved by China Government on Registration of Drug in 2014. CDE has many more products to be launched in 2014–2015 and they are prepared to compete in the US market within the next two years.
DISCLAIMER OF LIABILITY
The information published on this website is for the public’s reference only. No representation or warranty whatsoever, expressed or implied, is made as to its accuracy, reliability or completeness by HKSTP. Information and any other contents of this website are subject to change without notice.